ATE124865T1 - Verwendung von heterocyclischen verbindungen zur behandlung von bewusstseinsstörungen. - Google Patents

Verwendung von heterocyclischen verbindungen zur behandlung von bewusstseinsstörungen.

Info

Publication number
ATE124865T1
ATE124865T1 AT87311079T AT87311079T ATE124865T1 AT E124865 T1 ATE124865 T1 AT E124865T1 AT 87311079 T AT87311079 T AT 87311079T AT 87311079 T AT87311079 T AT 87311079T AT E124865 T1 ATE124865 T1 AT E124865T1
Authority
AT
Austria
Prior art keywords
consciousness
heterocyclic compounds
treat disorders
disorders
attentional
Prior art date
Application number
AT87311079T
Other languages
English (en)
Inventor
Michael Brian Tyers
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868630077A external-priority patent/GB8630077D0/en
Priority claimed from GB868630074A external-priority patent/GB8630074D0/en
Priority claimed from GB868630076A external-priority patent/GB8630076D0/en
Priority claimed from GB878707175A external-priority patent/GB8707175D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE124865T1 publication Critical patent/ATE124865T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT87311079T 1986-12-17 1987-12-16 Verwendung von heterocyclischen verbindungen zur behandlung von bewusstseinsstörungen. ATE124865T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB868630077A GB8630077D0 (en) 1986-12-17 1986-12-17 Medicaments
GB868630074A GB8630074D0 (en) 1986-12-17 1986-12-17 Medicaments
GB868630076A GB8630076D0 (en) 1986-12-17 1986-12-17 Medicaments
GB878707175A GB8707175D0 (en) 1987-03-25 1987-03-25 Medicaments

Publications (1)

Publication Number Publication Date
ATE124865T1 true ATE124865T1 (de) 1995-07-15

Family

ID=27449858

Family Applications (2)

Application Number Title Priority Date Filing Date
AT87311079T ATE124865T1 (de) 1986-12-17 1987-12-16 Verwendung von heterocyclischen verbindungen zur behandlung von bewusstseinsstörungen.
AT93201171T ATE152623T1 (de) 1986-12-17 1987-12-16 Verwendung von heterozyklischen derivaten zur herstellung von arzneimitteln

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT93201171T ATE152623T1 (de) 1986-12-17 1987-12-16 Verwendung von heterozyklischen derivaten zur herstellung von arzneimitteln

Country Status (7)

Country Link
US (1) US4985437A (de)
EP (3) EP0279990B1 (de)
JP (1) JP2608079B2 (de)
AT (2) ATE124865T1 (de)
DE (2) DE3752062T2 (de)
ES (1) ES2074981T3 (de)
GR (1) GR3017369T3 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4948803A (en) * 1986-11-21 1990-08-14 Glaxo Group Limited Medicaments for treatment on prevention of withdrawal syndrome
US5198447A (en) * 1986-11-21 1993-03-30 Glaxo Group Limited Medicaments
GB8820651D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
WO1990014347A1 (en) * 1989-05-24 1990-11-29 Nippon Shinyaku Co., Ltd. Indole derivatives and medicine
US5171745A (en) * 1990-07-13 1992-12-15 Du Pont Merck Pharmaceutical Company Method of treating neurological dysfunction using neutrotransmitter enhancers
US5342845A (en) * 1990-08-31 1994-08-30 Nippon Shinyaku Company Limited Indole derivatives and drugs
HU211081B (en) * 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
EP0492020A1 (de) * 1990-12-21 1992-07-01 Merrell Dow Pharmaceuticals Inc. Verwendung von bestimmten Estern von Hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-on und verwandter Verbindungen zur Behandlung von kognitiven Erkrankungen
IT1250629B (it) * 1991-07-04 1995-04-21 Boehringer Ingelheim Italia Uso dei derivati dell'acido benzimidazolin-2-oxo-1-carbossilico.
JPH08507514A (ja) * 1993-03-08 1996-08-13 藤沢薬品工業株式会社 脳血管性疾患を治療または予防するための薬物
GB9412995D0 (en) * 1994-06-28 1994-10-26 Prendergast Kenneth F Safety enhancing pharmaceutical compositions of an active indazole
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
AR036041A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
BR0212477A (pt) * 2001-09-12 2004-08-24 Upjohn Co 7-aza[2.2.1] bicicloheptanos substituìdos para o tratamento de doenças
HUP0402289A2 (hu) 2001-10-02 2005-02-28 Pharmacia & Upjohn Company Gyógyhatású azabiciklusos csoporttal helyettesített kondenzált heteroaril-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
AU2003217275A1 (en) * 2002-02-19 2003-09-09 Pharmacia And Upjohn Company Azabicyclic compounds for the treatment of disease
BR0307735A (pt) * 2002-02-19 2005-01-25 Upjohn Co Carboxamidas heteroaromáticas com ligação-n em ponte biciclìcas fundidas para o tratamento de doença
BR0307874A (pt) * 2002-02-20 2004-12-28 Upjohn Co Atividade de compostos azabicìclicos com receptor de acetilcolina nicotìnica alfa7
MXPA05004723A (es) * 2002-11-01 2005-12-05 Pharmacia & Upjohn Co Llc Compuestos que tienen ambas actividades del agonista alfa 7 nachr y el antagonista 5ht para el tratamiento de las enfermedades del snc.
GB201421161D0 (en) * 2014-11-28 2015-01-14 Ge Healthcare As Metal complex formulations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531083B1 (fr) * 1982-06-29 1986-11-28 Sandoz Sa Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments
JPS5936675A (ja) * 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
DE3445377A1 (de) * 1983-12-23 1985-07-04 Sandoz-Patent-GmbH, 7850 Lörrach Carbocylische und heterocyclische carbonsaeureester und -amide von ueberbrueckten und nicht ueberbrueckten cyclischen stickstoffhaltigen aminen oder alkoholen
ATE86110T1 (de) * 1984-12-20 1993-03-15 Sandoz Ag Behandlung von gastrointestinalkrankheiten durch anwendung von 5-ht3-antagonisten.
CH667657A5 (de) * 1985-01-07 1988-10-31 Sandoz Ag Carbocyclische und heterocyclische carbonylmethylen- und methylpiperidine und -pyrrolidine.
US4605652A (en) * 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
DE385517T1 (de) * 1985-03-14 1991-07-25 Beecham Group P.L.C., Brentford, Middlesex, Gb Arzneimittel zur behandlung von erbrechen.
US4624961A (en) * 1985-04-17 1986-11-25 A. H. Robins Company, Incorporated Method for enhancing memory or correcting memory deficiency with arylamidopyrazolidines and arylamidodiazabicycloalkanes
EP0498466B1 (de) * 1985-04-27 2002-07-24 F. Hoffmann-La Roche Ag Derivate von Indazole-3-carboxamide und -3-carboxylsäure
EP0247266B1 (de) * 1986-01-07 1993-03-10 Beecham Group Plc Indolderivate mit einer azabicyclischen Seitenkette, Verfahren zu ihrer Herstellung, Zwischenprodukte und pharmazeutische Zusammensetzungen
NL8701682A (nl) * 1986-07-30 1988-02-16 Sandoz Ag Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten.
DE3801659A1 (de) * 1988-01-21 1989-07-27 Boehringer Ingelheim Kg Tetrahydropyridin - derivate
CA1332151C (en) * 1988-01-28 1994-09-27 Roman Amrein Use of a benzamide to treat cognitive disorder
DE68912822T2 (de) * 1988-05-16 1994-06-09 Searle & Co 2-Amino-4,5-methylenadipinsäure-Verbindungen für die Behandlung von CNS-Erkrankungen.
YU150489A (sh) * 1989-08-10 1992-12-21 W.L. Gore & Co. Gmbh. Uređaj za ispitivanje odevnih predmeta na nepromočivost
ES2098273T3 (es) * 1989-10-16 1997-05-01 Hem Pharma Corp Diagnostico y tratamiento de los trastornos neuro-cognitivos asociados a una disfuncion inmunologica sistemica.
IE65997B1 (en) * 1990-05-11 1995-11-29 Sankyo Co Piperidyloxy- and quinuclidinyloxy- isoxazole derivatives their preparation and their therapeutic use

Also Published As

Publication number Publication date
ATE152623T1 (de) 1997-05-15
GR3017369T3 (en) 1995-12-31
DE3751404T2 (de) 1995-12-21
EP0559297A1 (de) 1993-09-08
EP0279990B1 (de) 1995-07-12
JPS63277623A (ja) 1988-11-15
EP0559297B1 (de) 1997-05-07
JP2608079B2 (ja) 1997-05-07
EP0551963A2 (de) 1993-07-21
EP0551963A3 (en) 1993-09-01
US4985437A (en) 1991-01-15
EP0279990A2 (de) 1988-08-31
DE3751404D1 (de) 1995-08-17
DE3752062D1 (de) 1997-06-12
EP0279990A3 (en) 1990-11-28
DE3752062T2 (de) 1997-09-11
ES2074981T3 (es) 1995-10-01

Similar Documents

Publication Publication Date Title
ATE124865T1 (de) Verwendung von heterocyclischen verbindungen zur behandlung von bewusstseinsstörungen.
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
EA199700156A1 (ru) Производные индола как антагонисты рецептора 5-нт
FI931370A (fi) Kvaeve innehaollande analoger av icke-aromatiska heterocykliska foereningar med en fusionerad ring
ES2174836T3 (es) Heterrociclos nitrogenados triciclicos condesados como antagonistas de receptor de la sustancia p.
DE3780972T2 (de) Verwendung von spezifischen n-methyl-d-aspartat-rezeptor-antagonisten zur praevention und behandlung von neurodegeneration.
DE3788057T2 (de) Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen.
DE3650647T2 (de) Arzneimittel zur Behandlung von Anxietas
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69530933D1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
ATE182590T1 (de) Heterozyklische verbindungen für die behandlung von kardiovaskular- und zentralnervensystem störungen
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE95064T1 (de) Verwendung von angiotensin-converting-enzyminhibitoren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit.
DE59209728D1 (de) VERWENDUNG VON ANTAGONISTEN ODER PARTIELLEN AGONISTEN AM 5-HT 1a-REZEPTOR ZUR BEHANDLUNG UND PRÄVENTION VON KOGNITIVEN STÖRUNGEN
DE3782028T2 (de) Verwendung von ketonderivaten zur behandlung von bewusstseinsstoerungen.
DE69007486D1 (de) Verwendung von calciumantagonisten für die behandlung von narben.
ATE179594T1 (de) Verwendung von ethisterone zur topischen behandlung von akne oder androgenetischer alopezie
DE3787796T2 (de) Anwendung heterozyklischer Derivate zur Herstellung von Arzneimitteln.
DE3751362D1 (de) 5-Aryl-3H-1,2,4-triazol-3-one und ihre Verwendung als Antikonvulsiva.
ES8502103A1 (es) Procedimiento para la obtencion de amidas del acido piperazin-1-il-acetico substituido
DE3785555D1 (de) Verwendung von guaifenesin zur behandlung urologischer beschwerden.
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen
DE3683330D1 (de) Verwendung von imidazolinylaminoisoindolen und verwandten verbindungen zur behandlung von hyperglykaemie.
ATE209910T1 (de) Verwendung von 6,7-substituierter 2- aminotetraline zur behandlung von zytokin- vermittleten entzündungszuständen
DE3782030D1 (de) Anwendung heterozyklischer dervate zur herstellung von arzneimitteln.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee